Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 5
2007 4
2008 7
2009 4
2010 3
2011 5
2012 8
2013 8
2014 9
2015 8
2016 9
2017 6
2018 5
2019 14
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

88 results
Results by year
Filters applied: . Clear all
Page 1
Filanesib for the treatment of multiple myeloma.
Algarín EM, Hernández-García S, Garayoa M, Ocio EM. Algarín EM, et al. Among authors: ocio em. Expert Opin Investig Drugs. 2020 Jan;29(1):5-14. doi: 10.1080/13543784.2020.1703179. Epub 2019 Dec 12. Expert Opin Investig Drugs. 2020. PMID: 31815551 Review.
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators. Mateos MV, et al. Among authors: ocio em. Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18. Lancet Haematol. 2019. PMID: 31327687 Clinical Trial.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. San-Miguel JF, et al. Among authors: ocio em. Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Lancet Oncol. 2014. PMID: 25242045 Clinical Trial.
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Dimopoulos MA, et al. Among authors: ocio em. Blood. 2016 Jul 28;128(4):497-503. doi: 10.1182/blood-2016-02-700872. Epub 2016 May 25. Blood. 2016. PMID: 27226434 Free PMC article. Clinical Trial.
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV. Spicka I, et al. Among authors: ocio em. Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25. Ann Hematol. 2019. PMID: 31240472 Free PMC article. Clinical Trial.
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF; Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups. Paiva B, et al. Among authors: ocio em. Blood. 2016 Jun 23;127(25):3165-74. doi: 10.1182/blood-2016-03-705319. Epub 2016 Apr 26. Blood. 2016. PMID: 27118453 Clinical Trial.
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma.
Mogollón P, Díaz-Tejedor A, Algarín EM, Paíno T, Garayoa M, Ocio EM. Mogollón P, et al. Among authors: ocio em. Cells. 2019 Nov 13;8(11):1432. doi: 10.3390/cells8111432. Cells. 2019. PMID: 31766279 Free PMC article. Review.
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Algarín EM, Díaz-Tejedor A, Mogollón P, Hernández-García S, Corchete LA, San-Segundo L, Martín-Sánchez M, González-Méndez L, Schoumacher M, Banquet S, Kraus-Berthier L, Kloos I, Derreal A, Halilovic E, Maacke H, Gutiérrez NC, Mateos MV, Paíno T, Garayoa M, Ocio EM. Algarín EM, et al. Among authors: ocio em. Haematologica. 2020 Mar;105(3):e116-e120. doi: 10.3324/haematol.2018.212308. Epub 2019 Jul 18. Haematologica. 2020. PMID: 31320555 Free PMC article. No abstract available.
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, Moreno C, Vidriales MB, Toboso DG, Cedena MT, Ocio EM, Lecumberri R, García de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Pérez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Prosper F, Martinez-Lopez J, Lecrevisse Q, Verde J, Mateos MV, Lahuerta JJ, Orfao A, San Miguel JF. Puig N, et al. Among authors: ocio em. Leukemia. 2019 May;33(5):1256-1267. doi: 10.1038/s41375-018-0308-5. Epub 2018 Dec 12. Leukemia. 2019. PMID: 30542145 Free article.
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.
Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J. Mateos MV, et al. Among authors: ocio em. Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15. Br J Haematol. 2019. PMID: 31090915 Clinical Trial. No abstract available.
88 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback